Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Interest & Investment Income (2016 - 2017)

IGC Pharma (IGC) has disclosed Interest & Investment Income for 7 consecutive years, with $114.0 as the latest value for Q3 2016.

  • On a quarterly basis, Interest & Investment Income rose 116.47% to $114.0 in Q3 2016 year-over-year; TTM through Sep 2016 was $2197.0, a 49.23% decrease, with the full-year FY2017 number at $1744.0, down 16.35% from a year prior.
  • Interest & Investment Income was $114.0 for Q3 2016 at IGC Pharma, down from $2013.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $81131.0 in Q1 2012 to a low of -$692.0 in Q3 2015.
  • A 5-year average of $7402.1 and a median of $1918.5 in 2013 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: soared 225400.0% in 2013, then tumbled 608.82% in 2015.
  • IGC Pharma's Interest & Investment Income stood at $2051.0 in 2012, then fell by 11.07% to $1824.0 in 2013, then dropped by 11.73% to $1610.0 in 2014, then tumbled by 95.65% to $70.0 in 2015, then surged by 62.86% to $114.0 in 2016.
  • Per Business Quant, the three most recent readings for IGC's Interest & Investment Income are $114.0 (Q3 2016), $2013.0 (Q1 2016), and $70.0 (Q4 2015).